PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

EuroPCR 2024 – Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial

2024-05-15
(Press-News.org) Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.  Among them is the LANDMARK trial.

Background and Methods  Key randomized controlled trials have compared surgical aortic valve replacement (SAVR) with transcatheter aortic valve implantation (TAVI) using one of two commercially available transcatheter heart valves (THVs) - either an intra-annular balloon-expandable valve (BEV) (Edwards Sapien, Sapien XT or Sapien 3) or a supra-annular self-expanding valve (SEV) (Medtronic CoreVavle, Evolut-R or Evolut Pro).  Other THV have been introduced subsequently and head-to-head comparisons with established BEV or SEV platforms have frequently demonstrated less favorable efficacy and safety profiles.

Myval is a novel BEV whose key differentiating characteristic is the availability of a wider range of prosthesis sizes (with 1.5 mm increments versus 3 mm for comparators), allowing precise matching of the implanted valve with a patient’s specific anatomy. The LANDMARK randomized controlled trial investigated its early safety and efficacy in comparison with two widely adopted contemporary THVs (the Edwards SAPIEN BEV and Medtronic Evolut SEV).

The primary hypothesis was non-inferiority of the Myval THV and the primary safety and efficacy endpoint at 30-day follow-up was the composite of all-cause death, any stroke, life-threatening or disabling bleeding, stage 2 or 3 acute kidney injury, major vascular complications, moderate or severe paravalvular leak and new permanent pacemaker implantation (all defined according to VARC-3 criteria).  Patients were included if considered clinically and anatomically suitable for a transfemoral TAVI procedure by their respective Heart Teams.  Bicuspid aortic valve phenotypes were included and there were no restrictions related to estimated surgical risk.

Results  A total of 768 patients (mean age 80 years) at low surgical risk undergoing transfemoral TAVI were randomised 1:1 to implantation of a Myval THV or an alternative contemporary TAVI device (BEV or SEV).

At 30 days, the primary composite endpoint occurred in 24.7% and 27.6 % of the Myval and control groups, respectively, denoting non-inferiority of the Myval THV compared to other contemporary THVs (risk difference -2.7%; one-sided upper 95% CI 3.6%; p<0·0001 for non-inferiority).  There were no significant differences in any individual components of the primary endpoint, and no differences in technical and device success (defined according to VARC-3 criteria).  Secondary endpoints, including rates of pacemaker implantation and improvements in hemodynamic parameters (mean pressure gradient and effective orifice area) were also similar in both study arms.

Key learnings  Previous head-to-head comparisons of new THVs with the established Edwards BEVs or Corevalve/Evolut SEVs confirmed that there is no class effect regarding the clinical benefits that patients can expect after TAVI, but demonstrated inferior safety and efficacy. Validation of the non-inferiority of the MyVal platform in comparison with the two most frequently used contemporary THVs in the LANDMARK TRIAL is therefore a significant finding. Importantly, the characteristics of the patients included in this trial reflect contemporary practice, incorporating patients at low and intermediate surgical risk, and 6.0-7.5% with a bicuspid aortic valve.  

Although these short-term outcomes are promising, longer-term information concerning hemodynamic performance and risk of structural valve deterioration will be required to confirm durability of the Myval THV in comparison with contemporary valves. Follow up out to 10 years is planned to address this key question.

 

 

NOTES TO EDITORS  Key information  Session: Hotline /Late-Breaking Trials: Major Late-Breaking Trials from EuroPCR 2024  Presentation: Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial  Presenter: Patrick W. Serruys  Palais des Congrès Porte Maillot – Paris, France  Wednesday 15 May 2024 – presentation time 09:30 CEST (session time 08:30-10:00) – Theatre Bleu  About EuroPCR 2024  The World-Leading Course in interventional cardiovascular medicine and the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) will take place from 14 to 17 May 2024, onsite at the Palais des Congrès, Paris, France. A digital package is also available for those unable to join in person. 

The detailed Course Programme is available on: https://www.pcronline.com/Courses/EuroPCR/Programme  

About PCR  The mission of PCR is to serve the needs of each individual patient by helping the global cardiovascular community to share knowledge, experience and practice. PCR offers a large range of many other educational meetings and resources for the continuing education of the interventional cardiovascular community. These include major annual courses across the globe, e-learning with high-profile PCR Webinars, courses specifically dedicated to valvular heart disease, tailor-made PCR Seminars on specific topics, online resources and medical publications such as EuroIntervention, the official journal of the EAPCI. 

Gateways to all PCR activities are available on www.pcronline.com

For further information, please contact Sally Collingridge: scollingridge@europa-group.com 

About the EAPCI   The European Association of Percutaneous Cardiovascular Interventions (EAPCI) is a branch of the European Society of Cardiology. Its mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions. This dynamic association represents a large community of over 8K EAPCI associates and over 1K full EAPCI members by helping them remain up to date in the constantly evolving field of PCI by publishing research and providing educational, training and certification programmes. The EAPCI also advocates for the best possible access to life saving treatments for patients through data-based advocacy at a European level.  

HELP FOR JOURNALISTS TO COVER EUROPCR 2024  Register and attend EuroPCR 2024 as a journalist 

Open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press, go to 
https://www.pcronline.com/Courses/EuroPCR/Press 

EuroPCR press releases can be found at 
https://www.pcronline.com/News/PCR-Press-Releases

For any press-related enquiries, please contact 
EuroPCR Press Coordinator, Isabelle Uzielli: iuzielli@europcr.com 

END


ELSE PRESS RELEASES FROM THIS DATE:

How does exercise benefit the brain?

2024-05-15
New research published in Aging Cell provides insights into how exercise may help to prevent or slow cognitive decline during aging. For the study, investigators assessed the expression of genes in individual cells in the brains of mice. The team found that exercise has a significant impact on gene expression in microglia, the immune cells of the central nervous system that support brain function. Specifically, the group found that exercise reverts the gene expression patterns of aged microglia to patterns seen in young microglia. Treatments that depleted ...

How will climate change affect the distribution of jellyfish and other gelatinous zooplankton in the Arctic Ocean?

2024-05-15
Gelatinous zooplankton, including jellyfish and other diverse, nearly transparent organisms, play important roles in marine ecosystems. Climate change is expected to significantly alter their populations and distributions. New research published in Limnology and Oceanography examines their fate in the Arctic Ocean, one of the fastest warming oceans on Earth. Investigators coupled three-dimensional species distribution models with oceanographic variables from the Coupled Model Intercomparison Project Phase 6. The analyses allowed the team to identify gelatinous ...

Researchers identify new marker for breast cancer prognosis

2024-05-15
A protein called retinitis pigmentosa GTPase regulator interacting protein 1-like (RPGRIP1L) performs various functions that are important for development and for health throughout life, and mutations in the RPGRIP1L gene have been linked to different diseases. New research published in The FASEB Journal indicates that expression levels of the RPGRIP1L gene might serve as a new prognostic marker for individuals with invasive breast cancer. When investigators examined breast tissue specimens from different women, they found that the ...

Can robot-inspired computer-assisted therapy benefit children with autism?

2024-05-15
A new study published in the Journal of Computer Assisted Learning introduces a novel Robot-Inspired Computer-Assisted Adaptive Autism Therapy (RoboCA3T) that leverages the natural affinity of children with autism spectrum disorder towards technology and robots. RoboCA3T harnesses the potential of robot-assisted therapies by incorporating robot avatars and integrating them with computer-assisted therapies through a web-based solution. When investigators assessed Childhood Autism Rating Scale scores before and after the intervention, ...

Does getting out and about in the community affect cognitive function?

2024-05-15
The extent of individuals’ mobility within their community—how much they get out and about—may be linked to their cognitive function, according to new research published in the Journal of the American Geriatrics Society. In the study of 7,016 Black and white adults aged 52 years and older who completed various questionnaires, greater community mobility was significantly associated with better cognitive function, although the association was small. Because higher atherosclerotic cardiovascular disease (ASCVD) risk is associated with both mobility limitations and cognitive decline, investigators ...

How do mindfulness, self-compassion, other-compassion, and need fulfillment affect satisfaction in midlife married couples?

2024-05-15
Many people practice mindfulness or self-compassion techniques in their everyday life as part of their normal self-care routine. Although many studies support the individual benefits of mindfulness and self-compassion, few have focused on romantic relationship outcomes. A new study published in Personal Relationships examined how mindfulness, self- and other-compassion, and need fulfillment relate to relationship and sexual satisfaction in midlife married couples. The study involved survey results from 640 adults aged 40–59 years who were residing in Canada and were married. Mindfulness is the nonjudgmental attention and awareness to present ...

Novel technique helps predict risk of a meniscus tear in the knee

2024-05-15
New research indicates that various features assessed through imaging tests can reveal an individual’s risk of developing meniscus tears, which is one of the most common knee injuries. The study, which is published in the Journal of Orthopaedic Research, was based on the use of radiomics, which unveils imperceptible patterns in medical images. Investigators used magnetic resonance images from 215 people with intact menisci at the start of the study who had 4-year meniscal status data. Over 4 years, 34 participants developed meniscus tears. Use of radiomics at the start of the study correctly classified 24 of these 34 cases and 172 of 181 controls with a sensitivity of 70.6% ...

Healthcare interpreters important for heart attack rehabilitation

Healthcare interpreters important for heart attack rehabilitation
2024-05-15
After a heart attack, foreign-born people are less likely to attend a relapse-preventing Heart School than native-born patients. But with access to a professional interpreter, participation increases. This was found in a study led by researchers at Linköping University, published in the journal IJC Heart & Vasculature. “Our conclusion is that healthcare should always strive to provide professional interpreters. For foreign-born patients, access to interpreters was associated with participation in Heart School, and the education provided there seems to have a similar and positive effect on treatment goals for both foreign-born ...

More women on hospital teams mean better surgery outcomes

2024-05-15
A new paper in the British Journal of Surgery, published by Oxford University Press, finds that care in hospitals with higher surgery team sex-diversity was associated with better post-operative outcomes for patients. In various industries, including business, finance, technology, education, and the law, many observers believe gender and sex-diversity is important not only for equity, but also because it enriches the output of teams because members of the team bring a variety of experiences and viewpoints to their jobs. However, there is limited evidence for the value of teams’ sex-diversity in healthcare. Most published reports have focused on individuals’ ...

Studying bubbles can lead to more efficient biofuel motors

Studying bubbles can lead to more efficient biofuel motors
2024-05-15
By studying how bubbles form in a drop of biodiesel, researchers at the University of Gothenburg can help future engines get the most energy out of the fuel. In an internal combustion engine, the fuel is distributed in small droplets in injection valves to maximise combustion. In the engine, the fuel droplets are pressurised to turn into gas and burn. When gas is formed, bubbles form inside the droplets and it is these that the researchers at the University of Gothenburg have studied using femtosecond lasers. Less emissions “The bubbles have a significant impact on the atomisation of biodiesel in engines. Therefore, our research is very important ...

LAST 30 PRESS RELEASES:

Nucleoporin93: A silent protector in vascular health

Can we avert the looming food crisis of climate change?

Alcohol use and antiobesity medication treatment

Study reveals cause of common cancer immunotherapy side effect

New era in amphibian biology

Harbor service, VAST Data provide boost for NCSA systems

New prognostic model enhances survival prediction in liver failure

China focuses on improving air quality via the coordinated control of fine particles and ozone

Machine learning reveals behaviors linked with early Alzheimer’s, points to new treatments

Novel gene therapy trial for sickle cell disease launches

Engineering hypoallergenic cats

Microwave-induced pyrolysis: A promising solution for recycling electric cables

Cooling with light: Exploring optical cooling in semiconductor quantum dots

Breakthrough in clean energy: Scientists pioneer novel heat-to-electricity conversion

Study finds opposing effects of short-term and continuous noise on western bluebird parental care

Quantifying disease impact and overcoming practical treatment barriers for primary progressive aphasia

Sports betting and financial market data show how people misinterpret new information in predictable ways

Long COVID brain fog linked to lung function

Concussions slow brain activity of high school football players

Study details how cancer cells fend off starvation and death from chemotherapy

Transformation of UN SDGs only way forward for sustainable development 

New study reveals genetic drivers of early onset type 2 diabetes in South Asians 

Delay and pay: Tipping point costs quadruple after waiting

Magnetic tornado is stirring up the haze at Jupiter's poles

Cancers grow uniformly throughout their mass

Researchers show complex relationship between Arctic warming and Arctic dust

Brain test shows that crabs process pain

Social fish with low status are so stressed out it impacts their brains

Predicting the weather: New meteorology estimation method aids building efficiency

Inside the ‘swat team’ – how insects react to virtual reality gaming 

[Press-News.org] EuroPCR 2024 – Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial